全文获取类型
收费全文 | 1085篇 |
免费 | 80篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 57篇 |
妇产科学 | 18篇 |
基础医学 | 94篇 |
口腔科学 | 31篇 |
临床医学 | 169篇 |
内科学 | 206篇 |
皮肤病学 | 19篇 |
神经病学 | 40篇 |
特种医学 | 245篇 |
外科学 | 103篇 |
综合类 | 21篇 |
预防医学 | 39篇 |
眼科学 | 9篇 |
药学 | 59篇 |
中国医学 | 5篇 |
肿瘤学 | 53篇 |
出版年
2024年 | 2篇 |
2023年 | 9篇 |
2022年 | 5篇 |
2021年 | 14篇 |
2020年 | 10篇 |
2019年 | 14篇 |
2018年 | 27篇 |
2017年 | 14篇 |
2016年 | 22篇 |
2015年 | 24篇 |
2014年 | 28篇 |
2013年 | 29篇 |
2012年 | 25篇 |
2011年 | 26篇 |
2010年 | 41篇 |
2009年 | 60篇 |
2008年 | 33篇 |
2007年 | 16篇 |
2006年 | 25篇 |
2005年 | 8篇 |
2004年 | 15篇 |
2003年 | 19篇 |
2002年 | 19篇 |
2001年 | 26篇 |
2000年 | 14篇 |
1999年 | 13篇 |
1998年 | 51篇 |
1997年 | 53篇 |
1996年 | 66篇 |
1995年 | 48篇 |
1994年 | 44篇 |
1993年 | 49篇 |
1992年 | 17篇 |
1991年 | 7篇 |
1990年 | 17篇 |
1989年 | 39篇 |
1988年 | 36篇 |
1987年 | 35篇 |
1986年 | 33篇 |
1985年 | 24篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 23篇 |
1981年 | 15篇 |
1980年 | 8篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 12篇 |
1976年 | 11篇 |
1975年 | 13篇 |
排序方式: 共有1172条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
C. Caramella F. Ferrari M. C. Bonferoni M. E. Sangalli M. De Bernardi Di Valserra F. Feletti M. R. Galmozzi 《Biopharmaceutics & drug disposition》1993,14(2):143-160
Six preparations were considered: three multiple unit dosage forms (micropellets in capsules) (D, E and G) and one matrix tablet (B) were experimental prolonged release formulations, two non-disintegrating tablets (A and C) were commercial products. The in vitro dissolution behaviour of the differing formulations was investigated using the USP XXII paddle apparatus. The in vivo study was effected on a panel of 12 healthy volunteers. The two commercial tablets (A and C) showed mean dissolution time (MDT) of 1.34 and 1.44 h and td of 91 and 92 min, respectively; for prolonged release formulations (B, E, D, and G) MDT ranged between 2.28 and 4.23 h and td between 149 and 291 min. The mean residence time (MRT) was 8.68 and 6.47 h for tablets A and C, respectively; it ranged between 9.62 and 10.24 h for the multiple unit formulations E, D, and G and was 11.27 h for matrix B. Formulation B also showed the higher apparent elimination half-life t1/2 (7.12 h), while apparent t1/2 for all the other formulations were very similar, ranging between 5.04 and 5.28 h. High variability between the various formulations was found for Cmax and AUC values, and no relationships could be established with the type of formulation. An in vitro/in vivo correlation was found for all the formulations examined on the basis of analogous parameters (MDT and MRT); (r = 0.83, p <0.05). In a few cases the Wagner-Nelson deconvolution method was applied to individual plasma level versus time curves and the corresponding absorption curves were obtained. In these cases the in vitro/in vivo correlation was tested on the basis of the comparison of the in vivo absorption curves with the in vitro dissolution profiles. This was accomplished using the ‘Levy's plot’ (per cent released versus per cent absorbed) approach and provided further support for the correlation found. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.